C’est une revolution dans l’univers de l’analyse de sang. Quotient, une société basée à Eysins (VD), aux portes de Nyon, met sur le marché une nouvelle technique qui permet d’obtenir des résultats complets d’un échantillon avec une grande rapidité. Ces derniers sont délivrés en trente-cinq minutes, contre plusieurs heures actuellement. Les débouchés s’annoncent prometteurs. Read more
Quotient aims to reduce blood testing time
Trending Topics
Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.
-
Unveiling The L.I.V.E Xchange showroom and innovation space
We are delighted to unveil The L.I.V.E. Xchange, our new showroom and innovation space, at our headquarters in Eysins, Switzerland. The L.I.V.E. Xchange was created to give our customers, development partners, distributors, and other stakeholders access to a dynamic environment
-
AliveDx and Rowad Medical Services sign distribution agreement in the Kingdom of Saudi Arabia
AliveDx and Rowad Medical Services have signed a distribution agreement, which will enable Rowad Medical Services to distribute AliveDx’s products, Alba and MosaiQ®, in the Kingdom of Saudi Arabia. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s
-
AliveDx held its first Golden Partners Meeting
Last week, AliveDx held its first Golden Partners Meeting at its headquarters in Eysins, Switzerland. For four consecutive days, our Golden Partners from all around the world engaged with our management team and representatives from our commercial, regulatory, and technical
-
MosaiQ® Abstract Presented at Annual ACR Convergence Meeting
We are excited to announce that our abstract on the microarray prototype for the serological detection of eleven IgG autoantibodies commonly found in Connective Tissue Diseases was presented at ACR Convergence 2023, held in San Diego, California. Our poster titled
-
AliveDx receives three IVDR CE marks for its Multiplexed Autoimmune Diagnostics Solution
AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD). Eysins, 24 October 2023 — AliveDx is proud to announce it has received three CE Marks for: Its MosaiQ Centromere
-
Unveiling an Exciting Rebranding Initiative: AliveDx
We are thrilled to announce a transformative milestone in our journey—a comprehensive rebranding effort aimed at better reflecting the company’s mission, values, and vision for the future.
